Washington University School of Medicine

Digital Commons@Becker

Open Access Publications

5-18-2021

Experience with liposomal amphotericin B in outpatient parenteral antimicrobial therapy

Yvonne J Burnett

Washington University School of Medicine in St. Louis

Andrej Spec

Washington University School of Medicine in St. Louis

Mohamed M Ahmed

Medical University of South Carolina

William G Powderly

Washington University School of Medicine in St. Louis

Yasir Hamad

Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

Burnett, Yvonne J; Spec, Andrej; Ahmed, Mohamed M; Powderly, William G; and Hamad, Yasir, "Experience with liposomal amphotericin B in outpatient parenteral antimicrobial therapy." *Antimicrobial agents and chemotherapy*. 65, 6. e01876-20 (2021).

https://digitalcommons.wustl.edu/open_access_pubs/10777

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Experience with Liposomal Amphotericin B in Outpatient Parenteral Antimicrobial Therapy

Yvonne J. Burnett,^{a,b*} Andrej Spec,^b Mohamed M. Ahmed,^c William G. Powderly,^b Yasir Hamad^b

^aDepartment of Pharmacy Practice, St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis, St. Louis, Missouri, USA

^bDivision of Infectious Diseases, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA

^cDepartment of Nephrology, Medical University of South Carolina, Charleston, South Carolina, USA

ABSTRACT Outpatient parenteral antimicrobial therapy (OPAT) is a safe, effective, and convenient treatment strategy for patients receiving intravenous antimicrobials in the outpatient setting; however, data are limited describing the use and safety of liposomal amphotericin B (L-AMB). Records of patients receiving L-AMB OPAT between 1/1/2015 and 7/31/2018 were retrospectively reviewed. The primary objective was to describe the OPAT patient population discharged on L-AMB and evaluate factors associated with readmission and adverse events (AEs). Analysis was performed to evaluate for predictors of worse outcomes. Forty-two patients (67% male, median age 50 years) were identified, most of whom were treated for histoplasmosis. The most common doses of L-AMB were 3 mg/kg ($n = 16$, 38%) or 5 mg/kg ($n = 14$, 33%) based on actual body weight. Twenty-six (62%) patients completed their anticipated course of L-AMB. Twenty-two (52%) patients were readmitted within 30 days of discharge; median time to readmission was 11 days (interquartile range [IQR] 5 to 18). While hypokalemia and acute kidney injury (AKI) were common, occurring in 26 (62%) and 20 (48%) patients, respectively, only 5 (12%) were readmitted to the hospital due to L-AMB-associated AEs. Ninety percent of patients achieved at least partial renal recovery within 30 days after L-AMB discontinuation. Factors significantly associated with AKI include higher L-AMB dose, lower serum potassium levels after therapy initiation, and receipt of potassium supplementation at discharge. L-AMB is associated with significant AEs; however, these results suggest that treatment is feasible in the outpatient setting with close monitoring, as the majority of AEs were managed effectively in an outpatient without long-term sequelae.

KEYWORDS amphotericin, OPAT, outpatient, nephrotoxicity, hypokalemia

Outpatient parenteral antimicrobial therapy (OPAT) allows outpatient continuation of intravenous (IV) antimicrobials, reducing hospital length of stay and health care-associated costs while increasing patient satisfaction (1–3). However, OPAT is not without risks and complications. Decreased provider supervision increases risk of undetected and untreated adverse events (AEs). Additionally, implementation of OPAT programs assisting in transitions of care and monitoring is low (4–6).

Available OPAT data primarily report antibiotic outcomes, but information is lacking regarding amphotericin B (AMB) for invasive fungal infections (IFIs) treatment. Patients with IFIs are often complex with significant comorbidities, like immune deficiency, malignancy, and transplant recipients, and frequently require prolonged durations of therapy (7–9). AMB remains the broadest spectrum systemic antifungal since its 1950s introduction and is often the most effective agent for many IFIs (9, 10). However, therapy is frequently limited by toxicity, including infusion reactions, electrolyte aberrations, and nephrotoxicity (10). Lipid formulations, now mainstays of therapy, are associated with less toxicity than that of conventional deoxycholate (11). Liposomal

Citation Burnett YJ, Spec A, Ahmed MM, Powderly WG, Hamad Y. 2021. Experience with liposomal amphotericin B in outpatient parenteral antimicrobial therapy. *Antimicrob Agents Chemother* 65:e01876-20. <https://doi.org/10.1128/AAC.01876-20>.

Copyright © 2021 American Society for Microbiology. All Rights Reserved.

Address correspondence to Yvonne J. Burnett, Yvonne.burnett@uhsp.edu.

* Present address: Yvonne J. Burnett, Department of Pharmacy, Missouri Baptist Medical Center, St. Louis, Missouri, USA.

Received 4 September 2020

Returned for modification 3 November 2020

Accepted 21 March 2021

Accepted manuscript posted online 12 April 2021

Published 18 May 2021

TABLE 1 Baseline and clinical characteristics^a

Characteristic	Median (IQR) or n (%) (N = 42)
Age	50 (37–62)
Sex (Male)	28 (67)
Comorbidities	
Malignancy	19 (45)
Solid tumor malignancy	3 (7)
Hematologic malignancy	16 (28)
Chemotherapy	15 (36)
Immunosuppressive medications (steroids, biologics, DMARDs)	9 (21)
Diabetes mellitus	6 (14)
Stem cell transplant recipients	6 (14)
Solid organ transplant recipients	1 (2)
Human immunodeficiency virus	3 (7)
Site of infection	
Disseminated	19 (45)
Pulmonary	11 (26)
Central nervous system	6 (14)
Gastro-intestinal/abdominal organs	4 (10)
Sinusitis	3 (7)
Adrenal	3 (7)
Endocarditis	2 (5)
Candidemia	2 (5)
Osteomyelitis	1 (2)
Urinary tract	1 (2)
Type of fungal infection	
Histoplasmosis	13 (31)
Aspergillus (including possible Aspergillus pneumonia)	7 (17)
Cryptococcus	6 (14)
Candida	5 (12)
Blastomyces	3 (7)
Mucorales	2 (5)
Others: <i>Fusarium</i> , <i>Irpex lacteus</i> , <i>Rhodoturula</i> , <i>Ustilago</i> , and possible dematiaceous fungus	5 (12) (one patient [2%] in each category)

^aIQR, interquartile range; DMARDs, disease modifying anti-rheumatoid drugs; HIV, human immunodeficiency virus.

amphotericin B (L-AMB) is the most widely used lipid formulation, but toxicity persists despite routine intensive monitoring, adding to the complexity of managing patients in less-supervised settings (11–16).

In the literature, AMB OPAT use is infrequent, ranging from 1 to 2% (2, 4, 12, 17–22). Additionally, these studies include various AMB products for both prophylactic and therapeutic indications. This study seeks to define patient populations receiving L-AMB OPAT for IFI treatment and determine rates and factors associated with readmission and AEs.

RESULTS

Forty-two patients received L-AMB OPAT between 01/01/2015 and 07/31/2018. Median age was 50 years (IQR 37 to 62) and 28 (67%) were male. The most common comorbidities were malignancy, receipt of immunosuppressive agents, diabetes mellitus, and receipt of stem cell transplant, in 19 (45%), 9 (21%), 6 (14%), and 6 (14%) patients, respectively. Histoplasmosis was the most common indication (13 [31%]), followed by aspergillosis (7 [26%]) and cryptococcosis (6 [14%]) (Table 1). Thirty-nine patients (93%) initiated therapy during hospital admission, with median length of stay of 9 days (IQR 5 to 22) (Table 2), while three (7%) started as outpatients. Most, 35 (83%), were managed with home infusion pharmacy and nursing services, four at

TABLE 2 Therapy characteristics and outcomes^a

Therapy characteristic or outcome	Median (IQR) or n (%) (N = 42)
Liposomal amphotericin B dose, mg/kg	4 (3–5)
Liposomal amphotericin B dose distribution	
<3 mg/kg	3 (7)
3 mg/kg	16 (38)
4 mg/kg	7 (17)
5 mg/kg	14 (33)
>5 mg/kg	2 (5)
Index hospitalization length of stay (39 patients), days ^b	9 (5–22)
Hypokalemia during index admission ^b	25 (64)
Significant hypokalemia during index admission ^b	13 (33)
Nadir potassium during index admission ^b	3.1 (2.8–3.5)
Serum creatinine at discharge, mg/dl	0.9 (0.7–1.1)
Serum potassium value at discharge, mmol/liter	3.8 (3.5–3.9)
Serum magnesium value at discharge, mg/dl	1.9 (1.7–2)
Concomitant nephrotoxic agent (vancomycin, tacrolimus)	8 (19)
OPAT location	
Home	35 (83)
SNF/LTAC	4 (10)
Infusion center	2 (7)
OPAT clinical course	
Duration	
Planned length, days	28 (14–42)
Actual total duration, including inpatient and outpatient (40 patients), days	26 (14–37)
Outpatient duration of therapy, days	14 (10–26)
Completion of L-AMB course fully as an outpatient	23 (55)
Median duration of therapy for those completing full course as an outpatient, days	18 (14–30)
Monitoring laboratory frequency, times per wk	2 (1–2.5)
Renal toxicity ^c	
Acute kidney injury	20 (48)
Maximum serum creatinine after discharge, mg/dl	1.29 (1–1.59)
Time to acute kidney injury, days	8.5 (5–14)
Patients received concomitant intravenous hydration with L-AMB	21 (50)
Electrolyte management ^c	
Hypokalemia (K < 3.5 mmol/liter) after discharge	26 (62)
Severe hypokalemia (K < 3.0 mmol/liter) after discharge	16 (38)
Potassium supplement prescribed at discharge	22 (52)
Nadir potassium after discharge, mmol/liter	3.1 (2.8–3.7)
Time to nadir hypokalemia, days	7 (4–9)
Magnesium supplement prescribed at discharge	12 (29)
Nadir magnesium after discharge, meq/liter	1.6 (1.5–1.9)
Readmission	
30-day hospital readmission	22 (52)
Time to readmission, days	11 (5–18)
Reason for 30-day hospital readmission (N = 22 [52%])	
Adverse drug reaction	5 (12)
Acute kidney injury	3
Hypokalemia	2
Worsening of infection	3 (7)
Other reasons, e.g., graft versus host disease, stem cell transplant, <i>Clostridioides difficile</i> infection, bacterial sepsis	14 (33)

^aIQR, interquartile range; L-AMB, liposomal amphotericin B; ID, infectious diseases; OPAT, outpatient parenteral antimicrobial therapy; SNF, skilled nursing facility; LTAC, long-term acute care facility.

^bAnalysis included only those who were started during a hospitalization and did not include three patients started as an outpatient.

^cWhen scored on the Naranjo scale, all cases met at least probable criteria due to temporal sequence, recognized AEs, and improvement upon withdrawal (32).

FIG 1 Outcomes of liposomal amphotericin B OPAT therapy.

postacute care facilities (PACFs), and two at infusion centers (Table 2). Labs were drawn a median of twice weekly (IQR 1 to 2.5). The most common L-AMB daily doses were 3 and 5 mg/kg, 16 (38%) and 14 (33%), respectively. Median total duration of therapy (inpatient and outpatient) was 26 days (IQR 14 to 37), and median OPAT duration was 14 days (IQR 10 to 26), resulting in 1,042 total OPAT days.

Twenty-two patients (52%) were readmitted within 30 days, occurring at a median of 11 days (IQR 5 to 18) (Table 2). Five patients (12%) were readmitted due to L-AMB-associated AEs (two for hypokalemia [serum potassium {K} 1.9 and 2.4 mmol/liter] and three for AKI) and three (7%) were readmitted due to worsening of IFI. Remaining readmissions, 14 (33%), were due to factors unrelated to L-AMB or IFI. No factors were significantly associated with readmission; however, readmissions were numerically higher in patients with malignancy (13/22 [59%] versus 6/20 [30%], odds ratio [OR] 3.37, 95% confidence interval [CI] 0.94 to 12.11).

Mortality occurred in two patients, both of whom developed AKI during therapy, due to progression of fungal disease (disseminated mold infection and resistant *Candida glabrata* candidemia).

Twenty-six (62%) patients completed their anticipated L-AMB duration (Fig. 1). This included patients who were readmitted but for whom L-AMB continued as planned. Twenty-three (55%) completed L-AMB as outpatients, with a median duration of 18 days (IQR 14 to 30 days) (Table 2). L-AMB was held in nine patients (21%) for AE management but was resumed and courses were completed successfully. Of those with early L-AMB discontinuation, 88% switched to an azole antifungal. Four patients experienced infusion reactions, two with rigors or chills and one each with fever and anaphylaxis.

Upon L-AMB OPAT initiation, median serum creatinine (SCr) was 0.9 mg/dl (IQR 0.7 to 1.1); however, 20 patients (48%) developed AKI at a median of 8.5 days (IQR 5 to 14). This occurred despite 50% ($n = 21$) receiving concurrent IV hydration. Factors associated with AKI (Table 3) included lower inpatient serum potassium after L-AMB initiation (3 versus 3.3 mmol/liter, $P = 0.04$), discharge prescription of potassium supplementation (70% versus 36%, OR 4.1, 95% CI 1.1 to 14.9), and higher L-AMB dose (4.6 versus 3.2 mg/kg, $P = 0.05$). Intravenous hydration was not associated with lower AKI risk (45% versus 55%, OR 0.7, CI 0.2 to 2.3). No patients with AKI developed hyperkalemia, and median outpatient maximum potassium was 4.3 mmol/liter (IQR 2.9 to 5).

Of those who developed AKI, five (25%) achieved full renal recovery within 30 days after discontinuation, while all surviving patients, 18 (90%), experienced at least partial recovery. At 1 year postdiscontinuation, 13 (65%) experienced full renal recovery at a median of 54 days (range 30 to 309). AKI management was

TABLE 3 Factors associated with acute kidney injury (bivariate analysis)^a

Variable	Acute kidney injury median (IQR) or <i>n</i> (%) (<i>N</i> = 20 [48%])	No acute kidney injury median (IQR) or <i>n</i> (%) (<i>N</i> = 22 [52%])	<i>P</i> value	Odds ratio	95% confidence interval
Age, yrs	56 (37–63)	48 (37–59)	0.80		
Sex, male	11 (55)	17 (77)	0.19	0.4	0.1–1.4
Diabetes mellitus	4 (20)	2 (9)	0.40	2.5	0.4–15.4
L-AMB dose, mg/kg	4.6 (3.3–5.1)	3.2 (3–4.4)	0.05		
Index hospitalization length of stay, days	9 (7–18)	10 (5–24)	0.65		
Frequency of laboratory monitoring, times per wk	2 (1–3)	2 (1–2)	0.34	1.3	0.6–2.5
Duration of therapy of L-AMB therapy, days	27.5 (14.5–35)	26 (14–43)	0.91		
Patient received concomitant IV hydration	9 (45)	12 (55)	0.54	0.7	0.2–2.3
Concomitant nephrotoxic agent	6 (30)	2 (9)	0.12	4.3	0.8–24.4
Serum creatinine at hospital discharge, mg/dl	0.9 (0.7–1.2)	0.87 (0.7–1)	0.45		
Peak serum creatinine, mg/dl	1.6 (1.4–1.8)	1 (0.9–1.2)	NA	NA	
Serum potassium at hospital discharge, mmol/liter	3.8 (3.5–3.9)	3.8 (3.5–3.9)	>0.99		
Potassium supplementation prescribed at discharge	14 (70)	8 (36)	0.03	4.1	1.1–14.9
Nadir potassium after discharge, mmol/liter	3.2 (2.9–3.8)	3.1 (2.7–3.6)	0.53		
Hypokalemia (<i>K</i> < 3.5 mmol/liter) during index hospitalization	14 (78)	10 (48)	0.10	3.9	0.9–15.7
Significant hypokalemia (<i>K</i> < 3.0 mmol/liter) during index hospitalization	8 (44)	4 (19)	0.16	3.4	0.8–14.2
Nadir potassium level during index hospitalization	3 (2.7–3.2)	3.3 (3.1–3.8)	0.04		
Serum magnesium at hospital discharge, mg/dl	1.8 (1.6–1.9)	1.9 (1.8–2)	0.08		
Magnesium supplementation prescribed at discharge	7 (35)	5 (23)	0.50	1.8	0.5–7.1
Nadir magnesium after discharge, mg/dl	1.6 (1.3–1.7)	1.8 (1.6–2)	0.06		

^aIQR, interquartile range; ID, infectious diseases; IV, intravenous; L-AMB, liposomal amphotericin B; NA, not applicable.

determined based on clinical judgment, resulting in 7 (35%) conversions to azole antifungals; however, 13 continued L-AMB. Seven (35%) were monitored and did not require therapy adjustment, 3 (15%) adjusted frequency to 48 h, and 1 (5%) adjusted frequency to thrice weekly. No patient required hemodialysis due to L-AMB nephrotoxicity.

Potassium was within normal limits for over 75% of patients upon initiation of L-AMB OPAT; however, despite supplementation in 22 (52%), 26 (62%) developed hypokalemia, median nadir of 3.1 mmol/liter (IQR 2.8 to 3.7). Sixteen (38%) developed severe hypokalemia, associated with age (40 versus 59 years, *P* = 0.05), L-AMB durations (30 versus 19.5 days, *P* = 0.02), and nadir magnesium (1.5 versus 1.7 meq/liter, *P* = 0.04).

DISCUSSION

To date, few reports detail L-AMB OPAT experiences (12, 21–23). This is the largest description of adult L-AMB OPAT patients, most of whom received daily infusions. We sought to determine rates and reasons for readmission and AEs to better understand this patient population and provide a description of L-AMB OPAT.

As expected with this complex population, readmission rates were high, occurring in 22 (52%) patients. However, most readmissions were unrelated to L-AMB, 14 (33%), with only 5 (12%) due to L-AMB-associated AEs (3 AKI and 2 hypokalemia). No factors were significantly associated with readmission; however, patients with malignancy were more frequently readmitted. L-AMB-associated readmission rates are similar to those from a previous study of outpatient amphotericin (12%); however, nonlipid AMB formulations were included in that study (12). In a study reporting thrice-weekly L-AMB OPAT, readmissions occurred in 22%, but only one (6%) readmission was attributed to L-AMB AKI (21). L-AMB-associated readmissions occurred in 17% (2/12) of patients in a study of antifungal OPAT that also utilized thrice-weekly administration (22).

High AE rates (20 to 72%) associated with lipid formulations are most notably due to AKI, varying between 9 and 25%, and electrolyte abnormalities (12–14). Compared to those in AMB deoxycholate, incidences of nephrotoxicity and infusion reactions are

lower with L-AMB and other lipid formulations (14, 24). Previous data suggest that there may not be a strong association with AEs and L-AMB dose; however, we noted an association with increased L-AMB dose and AKI (24–26). Most data regarding L-AMB-associated AEs describe inpatients, but in one study evaluating outpatient AMB, nephrotoxicity occurred in 50% of adults (12).

Conflicting nephrotoxicity definitions are present in AMB literature. These ranged from our definition, 0.5 mg/dl or 50% increase from baseline SCr, to ≥ 1 mg/dl increase or doubling of baseline SCr (11, 12, 14, 21, 24). As such, rates range from 10 to 56% depending on definitions used (11, 12, 14, 21, 24). A more conservative definition was used in this study, reflecting clinical practice of our OPAT program.

Sodium loading has reduced nephrotoxicity in hospitalized patients receiving AMB deoxycholate (12, 27, 28). Half of our patients received sodium loading via IV hydration with normal saline pre- and postinfusion upon OPAT initiation; however, this rose to 31 (74%) after intervention by the OPAT team. This is consistent with sodium loading practices reported in a survey of inpatient clinical pharmacists regarding prophylactic strategies to prevent AMB lipid formulation AEs, in which 68% reported routine use of IV fluid boluses (29), and similar to a previous report of community-based AMB, in which 50% received sodium loading (12). Unlike AMB deoxycholate, a trend toward lower nephrotoxicity was not seen in patients who received sodium loading, and it is unclear whether this benefit exists for L-AMB, as studies have not assessed effect on lipid formulations. Conversely, excessive fluid loading may play a role in exacerbating potassium wasting in the setting of magnesium deficiency (30).

Previous studies reporting AMB OPAT found that high rates of nephrotoxicity occurred in older patients, those who had received a solid organ transplant, and those who were receiving concomitant cyclosporine (12). We observed an association with lower inpatient potassium levels and potassium supplementation on discharge. It is possible that hypokalemia is an early sign of L-AMB-induced nephrotoxicity. Magnesium deficiency may exacerbate hypokalemia and render it refractory to treatment by potassium replacement (30). As such, patients with magnesium deficiency may be unable to replete potassium stores with potassium supplementation alone.

While AKI occurred frequently, no patient required hemodialysis. Patients achieved full renal recovery after discontinuation up to a rate of 65%, with 25% recovering within 30 days, similar to the results in prior reports (31). However, it should be noted for those with incomplete renal recovery that there may be implications affecting future therapy choices for underlying disease, emphasizing that L-AMB is not benign. While two patients died and experienced worsening renal function while on L-AMB, mortality was attributed to worsening infection. Inpatient management for patients at high risk for complications and those indicated for shorter courses may provide an opportunity for closer monitoring, allowing for earlier AE detection.

AEs were common, requiring close supervision by the OPAT team, which allowed for attentive and frequent laboratory monitoring, timely electrolyte replacement, and therapy adjustments. Over the last decade, OPAT team utilization has expanded, allowing for more comprehensive outpatient management. In a 2018 infectious diseases (ID) physician survey, 36% reported OPAT program utilization, up from 26% in 2012 (5, 6). Despite increased OPAT programs, significant barriers to care still exist.

IDSA's 2018 Clinical Practice Guidelines for the Management of OPAT recommends at least twice-weekly monitoring of potassium and SCr and weekly liver function tests (LFT) and complete blood counts (CBC) for L-AMB (1). In a survey of OPAT practices among adult ID physicians, 415/450 responded regarding L-AMB monitoring frequency; 47% reported twice-weekly monitoring, followed by once- (24%) and thrice-weekly (22%) monitoring (5). The Washington University School of Medicine (WUSM) ID OPAT team provides recommendations for thrice-weekly basic metabolic panels and once-weekly CBC and LFTs, guiding providers ordering laboratory studies on discharge. Despite this recommendation, we found that patients most often received twice-weekly studies (IQR 1 to 2.5). Patients with severe hypokalemia received more

frequent monitoring, likely due to increased monitoring after supplementation and trending potassium losses. High-frequency monitoring may not be feasible for all situations, but we agree with at least twice-weekly laboratory monitoring.

Barriers to OPAT transitions of care include appropriate discharge ordering of laboratory studies, access to outpatient laboratory data, and communication between OPAT teams and patients or PACF (6). First-hand experience in management of this population reveals that while barriers may be overcome by a dedicated and efficient OPAT team, significant manpower is necessary to address these issues. Additionally, clear and efficient communication among team members and patients is paramount, due to frequent therapy adjustments to mitigate AEs. Appropriate patient selection, of stable patients in whom prolonged hospitalization may be detrimental, also aids in successful OPAT courses. Developing action plans in anticipation of AEs, such as thresholds for therapy adjustments or electrolyte replacement, allows for quick action from the OPAT team and decreases time to intervention. In review of these data, reduction in L-AMB frequency may be an effective management strategy given L-AMB's long half-life, as seen in a few recent reports (21–23).

Limitations are those inherent to retrospective studies, as data were collected from chart review and limited to provider documentation. While numbers were small, given the rarity of L-AMB OPAT, it is a relatively large study. The small sample size limits abilities to assess readmission and AE contributing factors, though some associations may be helpful when caring for this challenging patient population.

Strength of this study lies in examination of L-AMB OPAT in the current era of more prevalent OPAT programs. Few studies have evaluated outpatient AMB and included prolonged study periods (5 to 10 years) and multiple AMB formulations. This study is unique, as prophylactic dosing was excluded. Patients received higher and more frequent dosing than those on prophylaxis, allowing for inclusion of a population more likely to experience AEs. In addition, all patients in this study received L-AMB, while previous studies report on mixed use of AMB deoxycholate and lipid formulations (12, 18–20). This study provided real-life experience with L-AMB OPAT, reporting clinically relevant outcomes, including readmission, significant hypokalemia, AKI, and associated factors.

Treatment with L-AMB OPAT is feasible but not without risks. With close monitoring and early intervention, OPAT teams can effectively manage a majority of L-AMB-associated AEs, without readmission or long-term sequelae. As OPAT programs continue to expand, additional work is needed to mitigate barriers to effective OPAT care, such as laboratory data access, correct discharge laboratory monitoring orders, and detecting transitions of care errors in these high-risk patients.

MATERIALS AND METHODS

This retrospective cohort consists of patients of ≥ 18 years who were managed by Washington University School of Medicine (WUSM) in St. Louis, Division of Infectious Diseases (ID) OPAT team receiving outpatient L-AMB from 01/01/2015 to 07/31/2018. Only L-AMB treatments prescribed for therapeutic purposes were included, excluding lower prophylactic doses. The WUSM ID OPAT team, consisting of an ID physician and pharmacist, midlevel providers, and nurses, coordinates transitions of care, monitors laboratory results (at minimum once weekly), and cares for $>1,500$ patients annually. Patients were identified utilizing the OPAT database maintained by clinic nurses and ID pharmacist. Patients are referred to the OPAT team via ID consult during hospitalization at Barnes-Jewish Hospital, a 1,368-bed academic medical center, or outpatient referral. Patients received L-AMB at home with home infusion pharmacy and nursing, at postacute care facilities (PACF), or at outpatient infusion centers.

Data points were abstracted from the electronic medical record utilizing a standardized data collection form by two abstractors and included patient demographics, comorbidities, concomitant medications, laboratory data, IFI indication, L-AMB dosage, electrolyte supplementation, IV hydration, 30-day hospital readmission data, and reported AEs. Discrepancies were resolved by discussion with study investigators (Y. J. Burnett, Y. Hamad). Data were managed using REDCap (Research Electronic Data Capture), a secure, web-based application hosted by Washington University School of Medicine Institute for Informatics, Informatics Core Services. Deidentified data were downloaded and stored via a secure server for statistical analysis. The study was approved by the Human Research Protection Office at Washington University in St. Louis.

Study definitions include the following. Acute kidney injury (AKI): 0.5 mg/dl or 50% increase from baseline serum creatinine (SCr). Full renal recovery: return to 50% of baseline SCr at 30 days and 1 year

after L-AMB discontinuation. Partial renal recovery: decrease by one stage of chronic kidney disease. Hypokalemia: $K < 3.5$ mmol/liter. Severe hypokalemia: $K < 3.0$ mmol/liter. Hypomagnesemia: $Mg < 1.5$ meq/liter. Infusion reactions: chills, fever, nausea, vomiting, dyspnea, chest pain, hypotension, and muscle spasm during or immediately following L-AMB infusion. AEs were classified in accordance with the Naranjo adverse drug reaction probability scale (32). Indication and planned duration of therapy were obtained from the ID provider note. For indefinite or long-term planned durations, 90 days was used as an estimate of how long patients may tolerate therapy.

Descriptive statistics analyzed baseline characteristics, care-related measures, and readmissions. Chi-square test analyzed categorical values, while Wilcoxon rank sum was used for continuous values. Odds ratios and 95% confidence intervals were calculated for categorical variables. Missing values were eliminated from analysis.

ACKNOWLEDGMENTS

The authors received no financial support for this research. Andrej Spec receives grant funding from Astellas and Mayne and performs advisory work for Scynexis, Minnetronix, and Viamet. Data were abstracted by Ara Gharabagi and Ciara Kellogg.

REFERENCES

- Norris AH, Shrestha NK, Allison GM, Keller SC, Bhavan KP, Zurlo JJ, Hersh AL, Gorski LA, Bosso JA, Rathore MH, Arrieta A, Petrak RM, Shah A, Brown RB, Knight SL, Umscheid CA. 2019. 2018 IDSA clinical practice guideline for the management of outpatient parenteral antimicrobial therapy. *Clin Infect Dis* 68:e1–e35. <https://doi.org/10.1093/cid/ciy745>.
- Hoffman-Terry ML, Fraimow HS, Fox TR, Swift BG, Wolf JE. 1999. Adverse effects of outpatient parenteral antibiotic therapy. *Ann J Med* 106:44–49. [https://doi.org/10.1016/S0002-9343\(98\)00362-3](https://doi.org/10.1016/S0002-9343(98)00362-3).
- Huang V, Ruhe JJ, Lerner P, Fedorenko M. 2018. Risk factors for readmission in patients discharged with outpatient parenteral antimicrobial therapy: a retrospective cohort study. *BMC Pharmacol Toxicol* 19:50. <https://doi.org/10.1186/s40360-018-0240-3>.
- Williams DN, Baker CA, Kind AC, Sannes MR. 2015. The history and evolution of outpatient parenteral antimicrobial therapy (OPAT). *Int J Antimicrob Agents* 46:307–312. <https://doi.org/10.1016/j.ijantimicag.2015.07.001>.
- Lane MA, Marschall J, Beekmann SE, Polgreen PM, Banerjee R, Hersh AL, Babcock HM. 2014. Outpatient parenteral antimicrobial therapy (OPAT) practices among adult infectious diseases physicians. *Infect Control Hosp Epidemiol* 35:839–844. <https://doi.org/10.1086/676859>.
- Hamad Y, Lane M, Beekmann S, Polgreen P, S Perspectives Of K. 2019. Perspectives of United States-based infectious diseases physicians on outpatient parenteral antimicrobial therapy practice. *Open Forum Infect Dis* 6: ofz363. <https://doi.org/10.1093/ofid/ofz363>.
- Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. 2016. Clinical practice guidelines for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. *Clin Infect Dis* 62:e1–e50. <https://doi.org/10.1093/cid/civ933>.
- Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA, Infectious Diseases Society of America. 2007. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. *Clin Infect Dis* 45:807–825. <https://doi.org/10.1086/521259>.
- Nett JE, Andes DR. 2016. Antifungal agents: spectrum of activity, pharmacology, and clinical indications. *Infect Dis Clin North Am* 30:51–83. <https://doi.org/10.1016/j.idc.2015.10.012>.
- Dodds AE, Lewis R, Lewis JS, Martin C, Andes D. 2006. Pharmacology of systemic antifungal agents. *Clin Infect Dis* 43:S28–S39. <https://doi.org/10.1086/504492>.
- Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, Mattiuzzi GN, Chandrasekar PH, Kontoyannis DP, Rolston KV, Walsh TJ, Champlin RE, Raad II. 2010. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and metanalysis. *Medicine (Baltimore, MD)* 89:236–244. <https://doi.org/10.1097/MD.0b013e3181e9441b>.
- Malani PN, Depestel DD, Riddell J, Bickley S, Klein LR, Kauffman CA. 2005. Experience with community -based amphotericin B infusion therapy. *Pharmacotherapy* 25:690–697. <https://doi.org/10.1592/phco.25.5.690.63591>.
- Steimbach LM, Tonin FS, Virtuoso S, Borba HHL, Sanches ACC, Wiens A, Fernandez-Llimós F, Pontarolo R. 2017. Efficacy and safety of amphotericin B lipid-based formulations—a systematic review and meta-analysis. *Mycoses* 60:146–154. <https://doi.org/10.1111/myc.12585>.
- Wade RL, Chaudhari P, Natoli JL, Taylor RJ, Nathanson BH, Horn DL. 2013. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex. *Diagn Microbiol Infect Dis* 76:361–367. <https://doi.org/10.1016/j.diagmicrobio.2013.04.001>.
- Wingard JR, White MH, Anaissie E, Raffali J, Goodman J, Arrieta A. 2000. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. *Clin Infect Dis* 31:1115–1163. <https://doi.org/10.1086/317451>.
- Falci DR, da Rosa FB, Pasqualotto AC. 2015. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study. *Mycoses* 58:104–112. <https://doi.org/10.1111/myc.12283>.
- Rae N, Kenny C, Muldoon EG. 2019. Can intravenous antifungal therapy be safely used in the outpatient parenteral antimicrobial therapy (OPAT) setting? *Mycoses* 62:196–203. <https://doi.org/10.1111/myc.12874>.
- Berman SJ, Johnson EW. 2001. Out-patient parenteral antibiotic therapy (OPAT): clinical outcomes and adverse events. *Hawaii Med J* 60:31–33.
- Chapman ALN, Dixon S, Andrews D, Lillie PJ, Bazaz R, Patchett JD. 2009. Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. *J Antimicrob Chemother* 64:1316–1324. <https://doi.org/10.1093/jac/dkp343>.
- Durojaiye OC, Bell H, Andrews D, Ntziara F, Cartwright K. 2018. Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service. *Int J Antimicrob Agents* 51:26–32. <https://doi.org/10.1016/j.ijantimicag.2017.03.016>.
- van de Peppel RJ, Schauwvlieghe A, Van Daele R, Spriet I, van't Wout JW, Brüggemann RJ, Rijnders BJA, Hendriks BJC, de Boer MGJ. 2020. Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B. *Med Mycol* 58:874–877. <https://doi.org/10.1093/mmy/myz134>.
- Gil-Navarro MV, Luque-Marquez R, Báez-Gutiérrez N. 2020. Antifungal treatment administered in OPAT programs is a safe and effective option in selected patients. *Enferm Infect Microbiol Clin* 38:479–484. <https://doi.org/10.1016/j.eimc.2020.01.019>.
- Lewis PO, Khan I, Patel P. 2018. Successful stepdown treatment of pulmonary histoplasmosis with thrice-weekly liposomal amphotericin B in a hospital-associated outpatient infusion centre: a case report. *J Clin Pharm Ther* 43:269–272. <https://doi.org/10.1111/jcpt.12609>.
- Groll AH, Rijnders BJ, Walsh TJ, Adler-Moore J, Lewis RE, Brüggemann RJM. 2019. Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B. *Clin Infect Dis* 68:S260–S274. <https://doi.org/10.1093/cid/ciz076>.
- Walsh TJ, Yeldandi V, McEvoy M, Gonzalez C, Chanock S, Freifeld A, Seibel NI, Whitcomb PO, Jarosinski P, Boswell G, Bekersky I, Alak A, Buell D, Barret J, Wilson W. 1998. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. *Antimicrob Agents Chemother* 42:2391–2398. <https://doi.org/10.1128/AAC.42.9.2391>.

26. Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, Barrett J, Anaissie EJ. 2001. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with *Aspergillus* species and other filamentous fungi: maximum tolerated dose study. *Antimicrob Agents Chemother* 45:3487–3496. <https://doi.org/10.1128/AAC.45.12.3487-3496.2001>.
27. Branch RA. 1988. Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation. *Arch Intern Med* 148:2389–2394. <https://doi.org/10.1001/archinte.1988.00380110049010>.
28. Heidemann HT, Gerkens JF, Spickard WA, Jackson EK, Branch RA. 1983. Amphotericin B nephrotoxicity in humans decreased by salt repletion. *Am J Med* 75:476–481. [https://doi.org/10.1016/0002-9343\(83\)90353-4](https://doi.org/10.1016/0002-9343(83)90353-4).
29. Chastain DB, Giles RL, Bland CM, Franco-Paredes C, Henao-Martinez AF, Young HN. 2019. A clinical pharmacist survey of prophylactic strategies used to prevent adverse events of lipid-associated formulations of amphotericin B. *Infect Dis (Lond)* 51:380–383. <https://doi.org/10.1080/23744235.2019.1568546>.
30. Huang C, Kuo E. 2007. Mechanism of hypokalemia in magnesium deficiency. *J Am Soc Nephrol* 18:2649–2652. <https://doi.org/10.1681/ASN.2007070792>.
31. Personett HA, Kayhart BM, Barreto EF, Tosh P, Dierkhising R, Mara K, Leung N. 2019. Renal recovery following liposomal amphotericin B-induced nephrotoxicity. *Int J Nephrol* 2019:1–8. <https://doi.org/10.1155/2019/8629891>.
32. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. 1981. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther* 30:239–245. <https://doi.org/10.1038/clpt.1981.154>.